

DENİZ LENGERLİ

ASST. PROF.

Email : deniz.lengerli@gazi.edu.tr

Office Phone : [+90 312 202 3226](tel:+903122023226)

International Researcher IDs

ScholarID: SC5VVRMAAAAJ

ORCID: 0000-0001-9838-8995

Publons / Web Of Science ResearcherID: AHA-9329-2022

ScopusID: 57217036994

Yoksis Researcher ID: 329342



Learning Knowledge

Doctorate
2016 - 2021

Gazi University, Sağlık Bilimleri Enstitüsü, Turkey

Undergraduate
2010 - 2015

Gazi University, Eczacılık Fakültesi, Turkey

Dissertations

Doctorate, STUDIES ON THE SYNTHESIS AND ANTICANCER ACTIVITY OF NOVEL 2,4-DIAMINOPYRIMIDINE DERIVATIVES, Gazi University, Sağlık Bilimleri Enstitüsü, 2021

Academic Titles / Tasks

Assistant Professor
2023 - Continues

Gazi University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri

Lecturer
2020 - 2023

Gazi University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri

Supported Projects

- LENGERLİ D., Project Supported by Higher Education Institutions, Antikanser Etkili Kumarin Türevi Yeni Bileşiklerin Geliştirilmesi, 2024 - Continues
- LENGERLİ D., Project Supported by Higher Education Institutions, Yeni Çözünür Epoksit Hidrolaz sEH Enzim İnhibitörlerinin Geliştirilmesi, 2023 - 2024
- Banoğlu E., Çalışkan B., TUBITAK Project, Meme ve Karaciğer Kanserin Tedavisi için PI3K/Akt Sinyal Yolunu Hedefleyen Yeni Aday İlaç Molekül Geliştirme ve Ön klinik Çalışmaları, 2016 - 2019

Awards

1. Banoğlu E., Lengerli D., TÜBA-TEKNOFEST DOKTORA TEZ ÖDÜLÜ, Tüba, September 2022

Published journal articles indexed by SCI, SSCI, and AHCI

1. **Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification**
Saatci O., Akbulut O., Cetin M., Sikirzhyski V., ÜNER M., LENGERLİ D., O'Quinn E. C., Romeo M. J., ÇALIŞKAN B., BANOĞLU E., et al.
Cell Death and Differentiation, vol.30, no.5, pp.1305-1319, 2023 (SCI-Expanded)
2. **The 1,2,3-triazole 'all-in-one' ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool.**
Lengerli D., Ibis K., Nural Y., Banoglu E.
Expert opinion on drug discovery, vol.17, no.11, pp.1209-1236, 2022 (SCI-Expanded)
3. **Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with in Vitro Growth Inhibitory and in Vivo Antitumor Activity**
Turanlı S., NALBAT E., LENGERLİ D., İBİŞ K., Güntekin Ergün S., Akhan Güzelcan E., MUYAN M., Cetin-Atalay R., Çalışkan B., BANOĞLU E.
ACS Omega, vol.7, no.41, pp.36206-36226, 2022 (SCI-Expanded)
4. **A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate**
Akbulut O., Lengerli D., Saatci O., Duman E., ŞEKER U. Ö. Ş., Isik A., AKYOL A., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.
MOLECULAR CANCER THERAPEUTICS, vol.19, no.6, pp.1243-1254, 2020 (SCI-Expanded)

Articles Published in Other Journals

1. **Crystal structure and Hirshfeld surface analysis 4-(4-chlorophenyl)-5-methyl-3-[(2-methylphenyl)methoxy]phenyl}-1,2-oxazole**
Aydin A., AKKURT M., TURANLI S., LENGERLİ D., BANOĞLU E., Ozcelik N. D.
ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, vol.77, pp.346-356, 2021 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

1. **A NOVEL SERIES OF ANTIPYRINE-UREA ANALOGUES: DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE**
LENGERLİ D.
International Multidisciplinary Symposium on Drug Research and Development (DRD) 2023, 4 - 06 May 2023
2. **STUDIES ON THE SYNTHESIS AND ANTICANCER POTENTIAL OF NOVEL 2,4-DIAMINOPYRIMIDINE DERIVATIVES**
Lengerli D., Akbulut Çalışkan Ö., Çalışkan B., Şahin Ö., Banoğlu E.
The 9th Young Medicinal Chemist Symposium (EFMC-YMCS 2022), Nice, France, 8 - 09 September 2022
3. **DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL IMIDAZOLIDINONE-THIAZOLE AMIDE HYBRIDS AS INHIBITORS OF HUMAN SOLUBLE EPOXIDE HYDROLASE**
İbiş K., Lengerli D., Jordan P. M., Çalışkan B., Werz O., Banoğlu E.
9th EFMC Young Medicinal Chemists' Symposium, Nice, France, 8 - 09 September 2022
4. **TACC3 İnhibitörü Yeni 2,4-Diaminopirimidin Türevlerinin Sentezi, Anti-Kanser Etki Potansiyelleri ve İlaç Benzeri Özelliklerinin Değerlendirilmesi Üzerine Çalışmalar**
LENGERLİ D., AKBULUT ÇALIŞKAN Ö., ÇALIŞKAN B., ŞAHİN Ö., BANOĞLU E.
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Turkey, 26 August 2022
5. **Synthesis of 3,4-Diaryl-5-methylisoxazoles with Potent Antiproliferative Activity Against a Panel of**

Human Liver and Breast Cancer Cell Lines

LENGERLİ D., TURANLI S., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., BANOĞLU E.
EFMC-ISMIC EFMC-YMCS Virtual Poster Session, 09 September 2020

6. Synthesis of New Vicinal Diaryl Five-Membered Heterocyclic Compounds with Potential Anticancer Activity

TURANLI S., LENGERLİ D., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., BANOĞLU E.
8th International Drug Chemistry Conference, 27 February - 01 March 2020

7. A SMALL MOLECULE INHIBITOR OF TRANSFORMING ACIDIC COILED-COIL PROTEIN 3 (TACC3): A NOVEL THERAPEUTIC STRATEGY FOR THE TREATMENT OF BREAST CANCER

LENGERLİ D., Akbulut O., ÇALIŞKAN B., ŞAHİN Ö., BANOĞLU E.

11th Joint Meeting on Medicinal Chemistry 2019, PRAG, Czech Republic, 27 - 30 June 2019

8. Abstract 3871: A novel TACC3 inhibitor as an anti-cancer agent in breast cancer

Akbulut O., LENGERLİ D., Saatci O., Duman E., Seker U., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.

Experimental and Molecular Therapeutics, 29 March - 03 April 2019

9. A Novel TACC3 inhibitor as an anti-cancer agent in breast cancer

AKBULUT ÇALIŞKAN Ö., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.

30th EORTC-NCI-AACR Symposium, Dublin, Ireland, 13 - 16 November 2018

Patent

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., AU2022256380 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2022256380 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Akbulut B., Lim C., Cruz E., Vempati S., HK62023072323.6 ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 62023072323.6 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Şahin Ö., Akbulut Ö., JP7301958 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE, Patent, CHAPTER A Human Needs, The Invention Registration Number: 7301958 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Şahin Ö., Lengerli D., Akbulut Ö., US11622966 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE, Patent, CHAPTER A Human Needs, The Invention Registration Number: US11622966 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Muyan M., Atalay R., Erson Bengan A. E., Lengerli D., Güntekin S., Turanlı S., İbiş K., ANTİKANSER AKTİVİTEYE SAHİP YENİ VİSİNAL DİARİL HETEROSİKLİK BİLEŞİK TÜREVLERİ, Patent, CHAPTER A Human Needs, The Invention Registration Number: TR 2019 14610 B , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Şahin Ö., Akbulut Ö., EP3801529B1 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE, Patent, CHAPTER A Human Needs, The Invention Registration Number: EP3801529B1 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., IN202327073452 COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 202327073452 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Lim C., Cruz E., Vempati S., TW11113780-COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 11113780 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Vempati S., Lim C., Cruz E., KR10-2022-7020047-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: KR10-2022-7020047 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Vempati S., Lim C., Cruz E., CN 202080091759.9 (2022110200431050)-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: CN 115279754 A (2022072000921700) , Standard Registration, 2022

Banođlu E., alıřkan B., İbiř K., Lengerli D., řahin Ö., Akbulut Ö., Lim C., Cruz E., Vempati S., JP2022-527677-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2022-527677 , Standard Registration, 2022

Banođlu E., alıřkan B., İbiř K., Lengerli D., řahin Ö., Akbulut Ö., Lim C., Cruz E., Vempati S., EP20888312.4-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP/20888312.4 , Standard Registration, 2022

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin Ö., Vempati S., Lim C., Cruz E., PCT/US2022/024263 (WO2022/221194 A1) COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US22/24263 , Standard Registration, 2022

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin Ö., Akbulut Ö., Lim C., Vempati S., Cruz E., US17/776,767-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US17/776,767 , Standard Registration, 2022

Banođlu E., alıřkan B., Lengerli D., řahin Ö., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-HongKong, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 62021037626.0 , 2021

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin Ö., Lim C., Cruz E., Vempati S., COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US63173796 , 2021

Banođlu E., alıřkan B., Lengerli D., řahin Ö., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-CN, Patent, CHAPTER A Human Needs, The Invention Recourse Number: CN201980049280.6 , 2021

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin Ö., Akbulut Ö., Lim C., Vempati S., Cruz E., ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS (US/PCT), Patent, CHAPTER A Human Needs, The Invention Recourse Number: PCT/US/2020/060588 , 2020

Banođlu E., alıřkan B., řahin Ö., Lengerli D., Akbulut Ö., ANTI-KANSER AJANI OLARAK KULLANILABİLECEK YENİ POTANSİYEL TACC3 İNHİBİTÖRÜ (BRP-OZG-264), Patent, CHAPTER A Human Needs, The Invention Registration Number: 2018 07464 , Standard Registration, 2020

Banođlu E., alıřkan B., Lengerli D., řahin Ö., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-KR, Patent, CHAPTER A Human Needs, The Invention Recourse Number: KR10-2020-7037075 , 2020

Banođlu E., alıřkan B., řahin Ö., Lengerli D., Akbulut Ö., ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP19209120.5 , Standard Registration, 2019

Metrics

Publication: 14

Citation (WoS): 56

Citation (Scopus): 67

H-Index (WoS): 3

H-Index (Scopus): 4

Congress and Symposium Activities

8th International BAU Drug Design Congress, Audience, İstanbul, Turkey, 2022

9th EFMC Young Medicinal Chemists' Symposium, Attendee, Nice, France, 2022

VI. Ulusal Farmasötik Kimya Kongresi, Attendee, İstanbul, Turkey, 2022

8th International Drug Chemistry Conference, Attendee, Antalya, Turkey, 2020

Research Areas

